Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Precision BioSciences, Inc. (DTIL : NSDQ)

• Company Description    Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina. Number of Employees: 68

• Price / Volume Information    Yesterday's Closing Price: $6.54 Daily Weekly Monthly 20 Day Moving Average: 372,689 shares Shares Outstanding: 24.73 (millions) Market Capitalization: $161.71 (millions) Beta: 1.28 52 Week High: $8.82 52 Week Low: $3.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 63.91% 74.83% 12 Week 57.21% 66.15% Year To Date 57.21% 66.15%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 302 EAST PETTIGREW STREET SUITE A-100 - DURHAM,NC 27701 USA ph: 919-314-5512 fax: - ir@precisionbiosciences.com http://www.precisionbiosciences.com

• General Corporate Information    Officers Michael Amoroso - President; Chief Executive Officer and Director Kevin Buehler - Chairman and Director John Alexander Kelly - Chief Financial Officer Melinda Brown - Director Stanley Frankel - Director Peer Information Precision BioSciences, Inc. (CORR.) Precision BioSciences, Inc. (RSPI) Precision BioSciences, Inc. (CGXP) Precision BioSciences, Inc. (BGEN) Precision BioSciences, Inc. (GTBP) Precision BioSciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74019P207 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/21/26 Share - Related Items Shares Outstanding: 24.73 Most Recent Split Date: 2.00 (0.03:1) Beta: 1.28 Market Capitalization: $161.71 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.27 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.17 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/21/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.62 Price/Cash Flow: - Price / Sales: 4.72 EPS Growth vs. Year Ago Period: 111.25% vs. Previous Quarter: 119.57% Sales Growth vs. Year Ago Period: 5,261.13% vs. Previous Quarter: 263,007.69% ROE 12/31/25 - -122.60 09/30/25 - -233.77 06/30/25 - -176.47 ROA 12/31/25 - -48.98 09/30/25 - -78.93 06/30/25 - -69.05 Current Ratio 12/31/25 - 13.32 09/30/25 - 3.45 06/30/25 - 5.18 Quick Ratio 12/31/25 - 13.32 09/30/25 - 3.45 06/30/25 - 5.18 Operating Margin 12/31/25 - -171.99 09/30/25 - -13,096.56 06/30/25 - -7,159.79 Net Margin 12/31/25 - -133.45 09/30/25 - -11,977.36 06/30/25 - -6,205.79 Pre-Tax Margin 12/31/25 - -136.03 09/30/25 - -11,977.36 06/30/25 - -6,205.79 Book Value 12/31/25 - 4.03 09/30/25 - 1.25 06/30/25 - 3.07 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.24 09/30/25 - 1.35 06/30/25 - 0.66 Debt-to-Capital 12/31/25 - 19.54 09/30/25 - 57.36 06/30/25 - 39.63

Powered by Zacks Investment Research ©